drugset / Trial / NCT00549718

Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia

NCT00549718 ↗

Phase 3 Completed 489 enrolled Sumitomo Pharma America, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is more efficacious than placebo. The study will also evaluate the safety and tolerability of lurasidone as compared to placebo.

Timeline

Start
2007-10
Primary completion
2010-10
Completion
2010-10

Outcome

Met primary endpoint

paper Treatment with lurasidone 80 mg/day resulted in significantly greater improvement in PANSS total score compared with placebo (-23.4 versus -17.0; p < 0.05) at study endpoint (MMRM); PMID 23421963 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Lurasidone Small molecule 40 mg —
Subject Lurasidone Small molecule 80 mg —
Subject Lurasidone Small molecule 120 mg —

Indications